Navigation Links
Gene therapy may aid failing hearts
Date:3/26/2013

In an animal study, researchers at the University of Washington show that it was possible to use gene therapy to boost heart muscle function. The finding suggests that it might be possible to use this approach to treat patients whose hearts have been weakened by heart attacks and other heart conditions.

Led by University of Washington (UW) Professor and Vice Chair of Bioengineering Michael Regnier and Dr. Chuck Murry, director of the Center for Cardiovascular Biology and co-director of the Institute for Stem Cell and Regenerative Medicine at UW, the study appears online today in the journal Proceedings of the National Academy of Sciences (PNAS).

Normally, muscle contraction is powered by a molecule, the nucleotide called Adenosine-5'-triphosphate (ATP). Other naturally occurring nucleotides can also power muscle contraction, but, in most cases, they have proven to be less effective than ATP.

In an earlier study of isolated muscle, however, Regnier, Murry and colleagues had found that one naturally occurring molecule, called 2 deoxy-ATP (dATP), was actually more effective than ATP in powering muscle contraction, increasing both the speed and force of the contraction, at least over the short-term.

In the new PNAS study, the researchers wanted to see whether this effect could be sustained. To do this, they used genetic engineering to create a strain of mice whose cells produced higher-than-normal levels of an enzyme called Ribonucleotide Reductase, which converts the precursor of ATP, adenosine-5'-diphosphate or ADP, to dADP, which, in turn, is rapidly converted to dATP.

"This fundamental discovery, that dATP can act as a 'super-fuel' for the contractile machinery of the heart, or myofilaments, opens up the possibility to treat a variety of heart failure conditions," Regnier said. "An exciting aspect of this study and our ongoing work is that a relatively small increase in dATP in the heart cells has a big effect on heart performance."

The researchers found that increased production of the enzyme Ribonucleotide Reductase increased the concentration of dATP within heart cells approximately tenfold, and even though this level was still less than one to two percent of the cell's total pool of ATP, the increase led to a sustained improvement in heart muscle function, with the genetically engineered hearts contracting more quickly and with greater force.

"It looks as though we may have stumbled on an important pathway that nature uses to regulate heart contractility," Murry added. "The same pathway that heart cells use to make the building blocks for DNA during embryonic growth makes dATP to supercharge contraction when the adult heart is mechanically stressed."

Importantly, the elevated dATP effect was achieved without imposing additional metabolic demands on the cells, suggesting the modification would not harm the cell's functioning over the long-term.

The finding, the authors write, suggest that treatments that elevate dATP levels in heart cells may prove to be an effective treatment for heart failure.


'/>"/>

Contact: Clare LaFond
clareh@uw.edu
206-685-1323
University of Washington - Health Sciences/UW News, Community Relations & Marketing
Source:Eurekalert

Related biology technology :

1. Gene Therapy - Technologies, Markets and Companies
2. Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
3. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
4. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
5. Squamous Cell Cancer Responds to SPDT Therapy
6. Stem cell therapy reverses diabetes
7. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
8. UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
9. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
10. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
11. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Flagship Biosciences, the leader ... to its Board of Directors. Dr. Gillett recently retired from Charles River Laboratories ... and Chief Scientific Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River ...
(Date:5/3/2016)... York, NY (PRWEB) , ... May 03, 2016 ... ... and NeuroTech NYC , the sensor and data driven conferences, will take place ... UnitedHealth's Vidya Raman-Tangella on incorporating technology -- including AR/VR, ...
(Date:5/3/2016)... , May 3, 2016  Dr. Thomas P. ... in The Woodlands, Texas , now ... percent of treated fat cells in just 25-minutes, leaving ... to 90 percent of Americans report feeling bothered by ... fat reduction procedures are a growing industry. This innovative ...
(Date:5/3/2016)... Angeles, Calif (PRWEB) , ... May 03, 2016 ... ... of industry leading fertility clinics and IVF laboratories. A contingency of reproductive endocrinologists, ... to treat men and women experiencing infertility and to help them build families. ...
Breaking Biology Technology:
(Date:3/2/2016)... , March 2, 2016 ... announced the addition of the  "Global Biometrics ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... to grow at a CAGR of around ... ) has announced the addition of ...
(Date:3/1/2016)... 1, 2016 ... of the  "Global Biometric Access Control ... their offering. --> http://www.researchandmarkets.com/research/ghsgdt/global_biometric ... the  "Global Biometric Access Control Systems ... offering. --> Research and ...
(Date:3/1/2016)... and SAN FRANCISCO , March 1, ... Corp. and BitGo, Inc. extends biometric authentication to the ... private keys. Bitcoin transactions that ... per month in digital assets with over 10,000 transactions ... any startup. HYPR enables enterprises to keep encrypted biometric ...
Breaking Biology News(10 mins):